Cargando…
Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212601/ http://dx.doi.org/10.1016/S0016-5085(22)61422-7 |
| _version_ | 1784730636666273792 |
|---|---|
| author | Dubinsky, Marla C. Betts, Keith Eren, Devrim Tang, Wenxi Yin, Lei Gupte-Singh, Komal |
| author_facet | Dubinsky, Marla C. Betts, Keith Eren, Devrim Tang, Wenxi Yin, Lei Gupte-Singh, Komal |
| author_sort | Dubinsky, Marla C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212601 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92126012022-06-22 Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS Dubinsky, Marla C. Betts, Keith Eren, Devrim Tang, Wenxi Yin, Lei Gupte-Singh, Komal Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212601/ http://dx.doi.org/10.1016/S0016-5085(22)61422-7 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AGA Abstracts Dubinsky, Marla C. Betts, Keith Eren, Devrim Tang, Wenxi Yin, Lei Gupte-Singh, Komal Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
| title | Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
| title_full | Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
| title_fullStr | Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
| title_full_unstemmed | Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
| title_short | Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
| title_sort | su1500: comparative efficacy and safety of ozanimod and ustekinumab in patients with moderately to severely active ulcerative colitis |
| topic | AGA Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212601/ http://dx.doi.org/10.1016/S0016-5085(22)61422-7 |
| work_keys_str_mv | AT dubinskymarlac su1500comparativeefficacyandsafetyofozanimodandustekinumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT bettskeith su1500comparativeefficacyandsafetyofozanimodandustekinumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT erendevrim su1500comparativeefficacyandsafetyofozanimodandustekinumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT tangwenxi su1500comparativeefficacyandsafetyofozanimodandustekinumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT yinlei su1500comparativeefficacyandsafetyofozanimodandustekinumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT guptesinghkomal su1500comparativeefficacyandsafetyofozanimodandustekinumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis |